AVACTA GROUP PLC — Board/Management Information 2018

Mar 29, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3020J

Avacta Group PLC

29 March 2018

29 March 2018

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Directorate Change

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that Dr Michael Albin, one of the Group's Non-Executive Directors will be stepping down from the Board with effect from 30 March 2018.

Dr Alastair Smith, Group Chief Executive Officer, commented:

"I would like to thank Michael for his contribution to the Group over the last four years, his advice and support around the development of our Affimer technology has been invaluable. I am glad that Michael's association with Avacta will continue in an advisory capacity."

- Ends -

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  +44 (0) 844 414 0452 www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang	Tel:  +44 (0) 207 220 0500 www.finncap.com Tel:  +44 (0) 203 705 9318 Tel:  +44 (0) 203 705 9217 www.wgpartners.co.uk
Zyme Communications (Trade and Regional Media) Katie Odgaard Yellow Jersey PR (Financial Media and IR) Sarah Hollins	Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com  Tel: +44 (0)7764 947137 avacta@yellowjerseypr.com

To register for Avacta news alerts by email go to www.avacta.com/investor-news-email-alerts

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOALLFFEVTITFIT